Publications
- Jiaying Lyu, Tianjian Zhou, Shijie Yuan, Wentian Guo, and Yuan Ji.(2020) MUCE: Bayesian Hierarchical Modeling for the Design and Analysis of Phase 1b Multiple Expansion Cohort Trials. Under review.
- Tianjian Zhou, Wentian Guo, Yuan Ji. (2019) PoD-TPI: Probability-of-Decision Toxicity Probability Interval Design to Accelerate Phase I Trials. Statistics in Biosciences. Accepted.
- Ciara Nugent, Wentian Guo, Perter Mueller, Yuan Ji. (2019) Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Design. JCO Precision Oncology. Accepted.
- Zhou,T., Guo, W., & Ji, Y. (2019). PoD-TPI: Probability-of-DecisionToxicity Probability Interval Design to Accelerate Phase I Trials. arXivpreprint arXiv:1904.12981.
- Liu, M., Wang, S.J. and Ji, Y., (2019). The i3+3 design for phase I clinical trials. Journal of Biopharmaceutical Statistics
- Guo, W., Ji, Y., & Li, D. (2019). R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials. Journal of biopharmaceutical statistics, 1-14.
- Lyu, J., Curran, E., & Ji, Y. (2018). Bayesian Adaptive Design for Finding the Maximum Tolerated Sequence of Doses in Multicycle Dose-Finding Clinical Trials. JCO Precision Oncology, 2, 1-19.
- Lyu, J., Ji, Y., Zhao, N., & Catenacci, D. V. (2019). AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual‐agent dose finding trials. Journal of the Royal Statistical Society: Series C (Applied Statistics), 68(2), 385-410.
- Guo, W., Ji, Y., & Catenacci, D. V. (2017). A subgroup cluster‐based Bayesian adaptive design for precision medicine. Biometrics, 73(2), 367-377.
- Guo, W., Wang, S. J., Yang, S., Lynn, H., & Ji, Y. (2017). A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2. Contemporary clinical trials, 58, 23-33.
- Lee, J., Thall, P. F., Ji, Y., & Müller, P. (2016). A decision-theoretic phase I–II design for ordinal outcomes in two cycles. Biostatistics, 17(2), 304-319.
- Li, D. H., Whitmore, J. B., Guo, W., & Ji, Y. (2016). Toxicity and Efficacy Probability Interval Design for Phase 1 Adoptive Cell Therapy Dose-Finding Clinical Trials. Clinical Cancer Research, clincanres-1125.
- Yang, S., Wang, S. J., & Ji, Y. (2015). An integrated dose-finding tool for phase I trials in oncology. Contemporary clinical trials, 45, 426-434.
- Guo, W., Ni, Y., & Ji, Y. (2015). TEAMS: Toxicity-and efficacy-based dose-insertion design with adaptive model selection for phase I/II dose-escalation trials in oncology. Statistics in biosciences, 7(2), 432-459.
- Lee, J., Thall, P. F., Ji, Y., & Müller, P. (2015). Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity. Journal of the American Statistical Association, 110(510), 711-722.
- Xu, Y., Trippa, L., Müller, P., & Ji, Y. (2016). Subgroup-based adaptive (suba) designs for multi-arm biomarker trials. Statistics in biosciences, 8(1), 159-180.
- Pan, H., Xie, F., Liu, P., Xia, J., & Ji, Y. (2014). A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). Clinical Trials, 11(1), 49-59.
- Cai, C., Yuan, Y., & Ji, Y. (2014). A Bayesian dose finding design for oncology clinical trials of combinational biological agents. Journal of the Royal Statistical Society: Series C (Applied Statistics), 63(1), 159-173.
- Ji, Y., & Wang, S. J. (2013). Modified toxicity probability interval design: a safer and more reliable method than the 3+ 3 design for practical phase I trials. Journal of Clinical Oncology, 31(14), 1785.
- Ji, Y., & Wang, S. J. (2013). Safety concerns of the 3+ 3 design: A comparison to the mTPI design. In Topics in Applied Statistics (pp. 125-135). Springer, New York, NY.
- Pan, H., Ji, Y., Chen, Z., Li, C., & Xia, J. (2013). The choice of phase I bayesian adaptive designs in china. International Journal of Drug Discovery, 5(1), 185.
- Xie, F., Ji, Y., & Tremmel, L. (2012). A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials. Contemporary clinical trials, 33(4), 739-748.
- Ji, Y., Feng, L., Liu, P., Shpall, E. J., Kebriaei, P., Champlin, R., ... & Cooper, L. J. (2012). Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. Journal of biopharmaceutical statistics, 22(6), 1206-1219.
- Younes, A., Oki, Y., Bociek, R. G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, D., Galal, A., Besterman, J., Li, Z., Drouin, M., Patterson, T., Ward, M. R., Paulus, J. K., Ji, Y., Medeiros, L. J., & Li, Z. (2011). Phase II Study of Mocetinostat (MGCD0103) In Patients with Relapsed and Refractory Classical Hodgkin Lymphoma. The Lancet. Oncology, 12(13), 1222.
- Hu, B., Bekele, B. N., & Ji, Y. (2013). Adaptive dose insertion in early phase clinical trials. Clinical Trials, 10(2), 216-224.
- Ji, Y., Liu, P., Li, Y., & Nebiyou Bekele, B. (2010). A modified toxicity probability interval method for dose-finding trials. Clinical Trials, 7(6), 653-663.
- Bekele, B. N., Li, Y., & Ji, Y. (2010). Risk‐Group‐Specific Dose Finding Based on an Average Toxicity Score. Biometrics, 66(2), 541-548.
- Ji, Y., & Bekele, B. N. (2009). Adaptive randomization for multiarm comparative clinical trials based on joint efficacy/toxicity outcomes. Biometrics, 65(3), 876-884.
- Wang, M., Oki, Y., Pro, B., Romaguera, J. E., Rodriguez, M. A., Samaniego, F., McLaughlin, P., Hagemeister, F., Neelapu, S., Copeland, A., Samuels, B. I., Loyer, E. M., Ji, Y., & Samuels, B. I. (2009). Phase II study of yttrium-90–ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 27(31), 5213-5218.
- Bekele, B. N., Ji, Y., Shen, Y., & Thall, P. F. (2007). Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics, 9(3), 442-457.
- Li, Y., Bekele, B. N., Ji, Y., & Cook, J. D. (2008). Dose–schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. Statistics in medicine, 27(24), 4895-4913.
- Hu, B., Ji, Y., & Tsui, K. W. (2008). Bayesian estimation of inverse dose response. Biometrics, 64(4), 1223-1230.
- Fanale, M. A., Fayad, L. E., Pro, B., Samaniego, F., Zachariah, G., Nunez, C. A., Ji, Y., & Younes, A. (2008). A phase I study of bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma.
- Ji, Y., Li, Y., & Yin, G. (2007). Bayesian dose finding in phase I clinical trials based on a new statistical framework. Statistica Sinica, 531-547.
- Ji, Y., Li, Y., & Nebiyou Bekele, B. (2007). Dose-finding in phase I clinical trials based on toxicity probability intervals. Clinical Trials, 4(3), 235-244.
- Yin, G., Li, Y., & Ji, Y. (2006). Bayesian Dose‐Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios. Biometrics, 62(3), 777-787.